Supply Chain | November 27, 2021
Pharma firms switch to advanced pharma manufacturing
Market demand for significant volumes and quality of biopharma products would drive continuous manufacturing technologies
Market demand for significant volumes and quality of biopharma products would drive continuous manufacturing technologies
A first for the Asian market, addressing the health spends needs of over 200 million households.
The approval is for Cytomegalovirus, a type of Herpes virus
The NDA for Desidustat is based on positive data from the DREAM-ND and DREAM-D Phase 3 trials in patients with Chronic Kidney Disease (CKD) Not on Dialysis and Dialysis
The platform is a collaborative video solution that enables doctors and medical staff to deliver seamless health care experiences to patients through this digital interface
Hospitals and outpatient clinics can also digitally navigate patients from the time an order is placed, to when it is scheduled and completed through follow-up
CStone granted the exclusive rights to Hengrui for research, development, registration, manufacturing, and commercialization of anti-CTLA-4 mAb CS1002 in the Greater China region
Gavreto is the first and only precision medicine approved in the EU for first-line treatment of people with RET fusion-positive advanced NSCLC
Five potential first-in-class assets aimed at delivering significant long-term growth. Over 14 clinical development programs underway across portfolio and 11 new studies to start in 2022 across early- and late-stage pipeline
The system is a compact new addition to the Roche Molecular portfolio, providing efficiency, simplicity and timely results to laboratories of all sizes.
Subscribe To Our Newsletter & Stay Updated
